Article

Consider different iris lesion forms before final clinical diagnosis

Author(s):

Use these pearls to better diagnose and treat iris lesions.

 

Reviewed by Arun D. Singh, MD

Iris lesions can take several different forms, said Arun D. Singh, MD.

His overarching approach is to make an initial diagnosis on careful exam, generate a narrow differential diagnosis that includes two or three possibilities, and then order ancillary testing, said Dr. Singh, director, Department of Ophthalmic Oncology, Cleveland Clinic, Cleveland. After that, he comes up with a final clinical diagnosis.

Dr. Singh shared diagnostic and management tips for all types of iris lesions. For instance:
 

  • Consider different treatment approaches. “You can observe if you think it’s benign,” he said. “If it’s malignant, you can radiate with focal radiation or enucleate if it’s big.”

  • Try to differentiate a nevus from iris melanoma. This is not always easy to do, but signs that suggest melanoma include a history of recent growth, size of more than 3 mm, intrinsic vascularity, hyphema, and angle seeding.

  • Think about the different entities that could be present in the iris when making a diagnosis. These could include a melanocytic tumor, nonmelanocytic tumors, iris metastases, iris cysts, iridocorneal syndrome, and inflammatory conditions.

  • Have anterior chamber optical coherence tomography (OCT), gonioscopy, transillumination, and ultrasound biomicroscopy (UBM) ready to help with diagnosis.

  • Use UBM to view the ciliary body. “OCT is good for the iris but not for the ciliary body,” Dr. Singh said. One occurrence not all surgeons may be aware of is ciliary body nevis, he added.

  • Lean toward total excision, if feasible.

 

Reference

1. Singh AD. Small incision guarded hydroaspiration of iris lesions. Br J Ophthalmol. 2017 Mar 14.

 

 

Arun D. Singh, MD

E: singha@ccf.org

This article was adapted from Dr. Singh’s presentation during Cornea Subspecialty Day at the 2016 meeting of the American Academy of Ophthalmology. Dr. Singh did not indicate any proprietary interest in the subject matter.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.